Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

81. Constipation

Constipation TREATMENT OF CONSTIPATION IN PREGNANCY 0344 892 0909 TREATMENT OF CONSTIPATION IN PREGNANCY (Date of issue: March 2018 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Constipation is common in pregnancy and affects (...) approximately 40% of women. It is thought to be caused by progesterone-induced intestinal smooth muscle relaxation. There is very little published epidemiological information available on the potential risks associated with the use of laxatives during pregnancy, however most have minimal systemic absorption and are commonly used during pregnancy without concerns regarding teratogenic effects being raised. Initial treatment of constipation in pregnancy should be non-pharmacological, e.g. exercise, dietary

2014 UK Teratology Information Service

82. Treatments for constipation: a review of systematic reviews

Treatments for constipation: a review of systematic reviews Treatments for constipation: a review of systematic reviews Treatments for constipation: a review of systematic reviews CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Treatments for constipation: a review of systematic reviews. Ottawa: Canadian Agency for Drugs (...) and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions In adults and children with chronic constipation, polyethylene glycol (PEG), increased the frequency of stools relative to placebo, lactulose and milk of magnesia. Stool frequency was also increased in adults treated with prucalopride versus placebo. Laxatives and prucalopride may increase the risk of diarrhea. No conclusions can be drawn with regards to stool softeners or bulking agents. The available studies were generally of lower

2014 Health Technology Assessment (HTA) Database.

83. Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations from ESPGHAN and NASPGHAN

Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations from ESPGHAN and NASPGHAN Copyright 2014 by ESPGHAN and NASPGHAN. Unauthorized reproduction of this article is prohibited. Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations From ESPGHAN and NASPGHAN M.M. Tabbers, C. DiLorenzo, M.Y. Berger, C. Faure, M.W. Langendam, S. Nurko, A. Staiano, Y. Vandenplas, and M.A. Benninga ABSTRACT (...) Background:Constipationisapediatricproblemcommonlyencounteredby many health care workers in primary, secondary, and tertiary care. To assist medical care providers in the evaluation and management of children with functional constipation, the North American Society for Pediatric Gastro- enterology,Hepatology,andNutritionandtheEuropeanSocietyforPediatric Gastroenterology, Hepatology, and Nutrition were charged with the task of developing a uniform document of evidence-based guidelines. Methods: Nine clinical questions addressing diagnostic, therapeutic

2014 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

84. The role of endoscopy in the management of constipation

The role of endoscopy in the management of constipation GUIDELINE The role of endoscopy in the management of constipation This is one of a series of statements discussing the use of GI endoscopy in common clinical situations. The Stan- dards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE) prepared this guideline. Inpreparingthisdocument,MEDLINEdatabaseswereused to search for publications pertaining to this topic between January 1990 and December 2013 (...) of thepatient’scondition and available coursesof action. Therefore,clinical considerations mayleadan endoscop- ist to take a course of action that varies from the recom- mendations and suggestions proposed in this document. INTRODUCTION AND EPIDEMIOLOGY Constipation is a common symptom affecting 2% to 27% of the population and resulting in about 2.5 million physician visits in the United States annually. 2,3 The preva- lence of constipation is higher in women than in men 4 and increases with age. 5 Low socioeconomic

2014 American Society for Gastrointestinal Endoscopy

85. Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain. Full Text available with Trip Pro

Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain. Opioid-induced constipation is common and debilitating. We investigated the efficacy and safety of naloxegol, an oral, peripherally acting, μ-opioid receptor antagonist, for the treatment of opioid-induced constipation.In two identical phase 3, double-blind studies (study 04, 652 participants; study 05, 700 participants), outpatients with noncancer pain and opioid-induced constipation were randomly assigned to receive

2014 NEJM Controlled trial quality: predicted high

86. Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness

Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness CADTH Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions There remains a paucity of good quality evidence to support the use of docusate

2014 Health Technology Assessment (HTA) Database.

87. Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: a comparative effectiveness review

Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: a comparative effectiveness review Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: a comparative effectiveness review Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: a comparative effectiveness review Stein E, Berger Z, Hutfless S, Shah L, Wilson LM, Haberl E, Bass (...) EB, Clarke JO Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stein E, Berger Z, Hutfless S, Shah L, Wilson LM, Haberl E, Bass EB, Clarke JO. Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: a comparative effectiveness review. Rockville: Agency for Healthcare Research and Quality

2013 Health Technology Assessment (HTA) Database.

88. Auriculotherapy in relieving symptoms of constipation and improving quality of life for the elderly: a pilot project. (Abstract)

Auriculotherapy in relieving symptoms of constipation and improving quality of life for the elderly: a pilot project. 23249851 2013 09 30 2016 10 20 1024-2708 18 Suppl 6 2012 Dec Hong Kong medical journal = Xianggang yi xue za zhi Hong Kong Med J Auriculotherapy in relieving symptoms of constipation and improving quality of life for the elderly: a pilot project. 30-3 Li M K MK School of Science and Technology, The Open University of Hong Kong, Hong Kong SAR, China. mkli@ouhk.edu.hk Lee T F D TF (...) Suen K P L KP eng Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't China Hong Kong Med J 9512509 1024-2708 IM Aged Aged, 80 and over Analysis of Variance Auriculotherapy Constipation therapy Feasibility Studies Female Humans Male Pilot Projects Quality of Life Single-Blind Method Time Factors 2012 12 20 6 0 2013 4 12 6 0 2013 10 1 6 0 ppublish 23249851

2013 Hong Kong medical journal = Xianggang yi xue za zhi Controlled trial quality: uncertain

89. Methylnaltrexone bromide (Relistor) for opioid-induced constipation

Methylnaltrexone bromide (Relistor) for opioid-induced constipation Methylnaltrexone bromide (Relistor) for opioid-induced constipation Methylnaltrexone bromide (Relistor) for opioid-induced constipation NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Methylnaltrexone bromide (Relistor) for opioid-induced constipation (...) . Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Analgesics, Opioids; Constipation; Laxatives; Naltrexone Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health&Population Sciences, University

2013 Health Technology Assessment (HTA) Database.

90. Sacral nerve stimulation for constipation (Abstract)

Sacral nerve stimulation for constipation For over 10 years sacral nerve stimulation (SNS) has been used for patients with constipation resistant to conservative treatment. A review of the literature is presented.PubMed, MEDLINE and Embase databases were searched for studies demonstrating the use of SNS for the treatment of constipation.Thirteen studies have been published describing the results of SNS for chronic constipation. Of these, three were in children and ten in adults. Test (...) stimulation was successful in 42-100 per cent of patients. In those who proceeded to permanent SNS, up to 87 per cent showed an improvement in symptoms at a median follow-up of 28 months. The success of stimulation varied depending on the outcome measure being used. Symptom improvement correlated with improvement in quality of life and patient satisfaction scores.SNS appears to be an effective treatment for constipation, but this needs to be confirmed in larger prospective studies with longer follow-up

2013 EvidenceUpdates

91. Irritable bowel syndrome with constipation in adults: linaclotide

Irritable bowel syndrome with constipation in adults: linaclotide Irritable bowel syndrome with constipation in Irritable bowel syndrome with constipation in adults: linaclotide adults: linaclotide Evidence summary Published: 9 April 2013 nice.org.uk/guidance/esnm16 pathways Ov Overview erview The content of this evidence summary was up-to-date in April 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date (...) information. Key points from the evidence Linaclotide (Constella) is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GCCA), licensed for the symptomatic treatment of moderate-to-severe irritable bowel syndrome with constipation (IBS-C) in adults. It received a European marketing authorisation in November 2012 and is expected to be launched during the first half of 2013. Linaclotide has been evaluated in 2 double-blind, randomised, placebo-controlled trials of patients with IBS-C

2013 National Institute for Health and Clinical Excellence - Advice

92. Coping with Common GI Symptoms in the Community: A Global Perspective on Heartburn, Constipation, Bloating, and Abdominal Pain/Discomfort

Coping with Common GI Symptoms in the Community: A Global Perspective on Heartburn, Constipation, Bloating, and Abdominal Pain/Discomfort © World Gastroenterology Organisation, 2013 World Gastroenterology Organisation Global Guidelines Coping with common GI symptoms in the community A global perspective on heartburn, constipation, bloating, and abdominal pain/discomfort May 2013 Review Team Richard Hunt (co-chair, Canada/UK) Eamonn Quigley (co-chair, USA) Zaigham Abbas (Pakistan) Abraham (...) 4.6.3 Primary care doctor 23 4.6.4 Specialist 24 5 Bloating 25 5.1 Definition and description 25 5.2 Epidemiological notes 26 5.3 Diagnostic/symptoms remarks 26 5.4 Differential diagnosis 27 5.5 Alarm features 27 5.6 Bloating—management cascade 27 5.6.1 Bloating self-help 27 5.6.2 Pharmacist 28 5.6.3 Primary care doctor 28 5.6.4 Specialist 29 6 Constipation 29 WGO Global Guidelines Common GI symptoms (long version) 3 © World Gastroenterology Organisation, 2013 6.1 Definition and description 29 6.2

2013 World Gastroenterology Organisation

93. Constipation

Constipation American Gastroenterological Association If you're seeing this message, that means JavaScript has been disabled on your browser , please enable JS to make this app work.

2013 American Gastroenterological Association Institute

94. A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation Full Text available with Trip Pro

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C).This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients

2012 EvidenceUpdates Controlled trial quality: predicted high

95. Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety (Abstract)

Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide treatment in patients with irritable bowel syndrome with constipation (IBS-C) over 26 weeks.This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients

2012 EvidenceUpdates Controlled trial quality: predicted high

96. Lubiprostone (Amitiza) for chronic idiopathic constipation

Lubiprostone (Amitiza) for chronic idiopathic constipation Lubiprostone (Amitiza) for chronic idiopathic constipation Lubiprostone (Amitiza) for chronic idiopathic constipation NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Lubiprostone (Amitiza) for chronic idiopathic constipation. Birmingham: NIHR Horizon Scanning (...) Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Alprostadil; Chronic Disease; Constipations Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston

2012 Health Technology Assessment (HTA) Database.

97. Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain

Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Alprostadils; Chronic Pain; Constipation Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department

2012 Health Technology Assessment (HTA) Database.

98. Naloxegol (NKTR-118) for opioid-induced constipation

Naloxegol (NKTR-118) for opioid-induced constipation Naloxegol (NKTR-118) for opioid-induced constipation Naloxegol (NKTR-118) for opioid-induced constipation NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Naloxegol (NKTR-118) for opioid-induced constipation. Birmingham: National Horizon Scanning Centre (NHSC). Horizon (...) Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Analgesics, Opioids; Constipation; Laxatives; Naltrexone Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15

2012 Health Technology Assessment (HTA) Database.

99. Oxycodone HCI / naloxone HCI - Pain, Moderate to severe and relief of opioid-induced constipation

Oxycodone HCI / naloxone HCI - Pain, Moderate to severe and relief of opioid-induced constipation Common Drug Review CDEC Meeting – November 16, 2011; CDEC Reconsideration – January 18, 2012 Notice of CDEC Final Recommendation – January 25, 2012 Page 1 of 6 © 2012 CADTH CDEC FINAL RECOMMENDATION OXYCODONE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE RESUBMISSION (Targin – Purdue Pharma) Indication: Relief of Moderate to Severe Pain and Opioid-Induced Constipation Recommendation: The Canadian Drug (...) Expert Committee (CDEC) recommends that oxycodone hydrochloride/naloxone hydrochloride controlled release (CR) (Targin) not be listed. Reason for the Recommendation: The comparative clinical benefit of oxycodone/naloxone CR in patients with moderate to severe chronic pain and opioid-induced constipation is not established, because there are no randomized controlled trials (RCTs) comparing oxycodone/naloxone CR with less expensive opioid treatment in combination with an optimized laxative regimen

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

100. Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation

Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation BlueCross BlueShield Association. Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 27(4). 2012 Authors' objectives The objective of this assessment is to determine whether the wireless motility capsule (SmartPill®) improves health outcomes when used in the diagnosis and evaluation of gastroparesis and constipation, in patients presenting with clinical

2012 Health Technology Assessment (HTA) Database.